Kobayashi Pharmaceutical Co., Ltd. (4967) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Kobayashi Pharmaceutical Co., Ltd. (4967:JPX), powered by AI.

Current Price
¥5,468
P/E Ratio
111.2
Market Cap
406.5B
Sector
Consumer Defensive
What is the Kobayashi Pharmaceutical Co., Ltd. stock price forecast?

Kobayashi Pharmaceutical Co., Ltd. is currently trading at ¥5,468. View real-time AI analysis on Alpha Lenz.

What is Kobayashi Pharmaceutical Co., Ltd. insider trading activity?

View the latest insider trading data for Kobayashi Pharmaceutical Co., Ltd. on Alpha Lenz.

What is Kobayashi Pharmaceutical Co., Ltd.'s P/E ratio?

Kobayashi Pharmaceutical Co., Ltd.'s P/E ratio is 111.2.

Kobayashi Pharmaceutical Co., Ltd.

JPX · 4967
¥5,468-53(-0.96%)Market closedJPX regular session 09:00–15:00 JST
Ask about Kobayashi Pharmaceutical Co., Ltd.'s future dividend policy...
Alpha Chat Insight

Kobayashi Pharmaceutical Co., Ltd. trades at a P/E of 111.2 (premium valuation) with modest ROE of 1.7%.

Ask for details

Company Overview

Kobayashi Pharmaceutical Co., Ltd. is a prominent player in the pharmaceutical industry, specializing in developing, manufacturing, and selling consumer health products. The company's portfolio includes over-the-counter medications, health supplements, and household products that focus on improving everyday life. Kobayashi is renowned for providing innovative healthcare solutions that cater to both preventive and therapeutic needs. Its offerings are primarily aimed at individuals, aiming to address common health concerns such as allergies, colds, and skincare conditions, while also providing wellness and dietary supplements. With a strong focus on research and development, Kobayashi maintains its competitive edge by frequently releasing new products that meet the evolving demands of the healthcare market. With its headquarters in Japan, the company has successfully expanded its presence internationally, significantly impacting the consumer health sector across Asia, Europe, and North America. In the financial markets, Kobayashi Pharmaceutical Co. stands as a key player, representing the broader consumer health industry and contributing to advancements in public health.

CEOMr. Kazumasa Kobayashi
SectorConsumer Defensive
IndustryHousehold & Personal Products
Employees3,615

Company Statistics

FY 2025

Profile

¥406,480,184,000Market Cap
¥165,742,000,000Revenue
0.00Shares Out
3,615Employees

Margins

51.11%Gross
15.59%EBITDA
9.01%Operating
2.26%Pre-Tax
2.21%Net

Valuation

111.18P/E
1.93P/B
2.45EV/Sales
13.34EV/EBITDA
35.10P/FCF

Growth (CAGR)

-0.10%Rev 3Yr
1.95%Rev 5Yr
-17.59%Op Inc 3Yr
-10.47%Op Inc 5Yr
-43.25%Net Inc 3Yr
-28.22%Net Inc 5Yr

Returns

1.35%ROA
1.72%ROE
1.40%ROIC

Financial Health

¥62,314,000,000Cash & Cash Equivalents
¥2,007,000,000Net Debt
30.48%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Kobayashi Pharmaceutical Co., Ltd. (ticker: 4967) is a company listed on JPX in the Consumer Defensive sector (Household & Personal Products). It has approximately 3,615 employees. Market cap is $406.5B.

The current price is 5,468 with a P/E ratio of 111.18x and P/B of 1.93x.

ROE is 1.72% and operating margin is 9.01%. Annual revenue is $165.7B.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Kobayashi Pharmaceutical Co., Ltd. (4967) Stock Forecast 2026 ¥5,468 — Price, Financials & Analyst Targets | Alpha Lenz